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Abstract: Na/K-ATPase has been extensively studied for its ion pumping function, but, in the past
several decades, has been identified as a scaffolding and signaling protein. Initially it was found
that cardiotonic steroids (CTS) mediate signal transduction through the Na/K-ATPase and result
in the generation of reactive oxygen species (ROS), which are also capable of initiating the signal
cascade. However, in recent years, this Na/K-ATPase/ROS amplification loop has demonstrated
significance in oxidative stress related disease states, including obesity, atherosclerosis, heart failure,
uremic cardiomyopathy, and hypertension. The discovery of this novel oxidative stress signaling
pathway, holds significant therapeutic potential for the aforementioned conditions and others that
are rooted in ROS.
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1. Introduction
The Na/K-ATPase enzyme (“sodium pump”) is well known for its ion pumping function,
but was also discovered to have a scaffolding and signaling function by Dr. Zijian Xie in the late
1990s. Over the last twenty years, studies have shown that this signaling pathway, and alterations
with it, is involved with a number of clinical disorders, including cancer, chronic kidney disease,
and cardiovascular diseases, such as uremic cardiomyopathy [1,2]. Our recent work with obesity
models has provided evidence that the Na/K-ATPase signaling cascade activation worsens obesity,
diabetes, dyslipidemia, and atherosclerosis, as these conditions are all related to an imbalance of
oxidative stress (Figure 1) [3]. Na/K-ATPase and the signaling pathway present increasing importance,
given the therapeutic potential it holds for the aforementioned clinical disorders.
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Figure 1. Oxidative Stress Imbalance. Redox imbalance is central to the pathophysiology of chronic 
disorders, including obesity, metabolic syndrome, and cardiovascular diseases, such as 
atherosclerosis, and diabetes. These disorders are intertwined in a vicious, feed-forward loop of 
oxidative stress, which eventually leads to the development of end organ damage that is frequently 
seen with chronic disorders like these.  
2. Na/K-ATPase: Structure, Function, and the Xie Model of Signaling 
Na/K-ATPase primarily consists of three subunits denoted by α, β, and γ, with α and β subunits 
necessary for ion pumping. The α subunit contains the ATP, digitalis, and other ligand binding sites, 
and is considered the “catalytic subunit” [1]. The Na/K-ATPase α subunit, with 10 transmembrane 
domains, has four isoforms. The α1 isoform is found in all cells, whereas the α2 and α3 isoforms are 
expressed in skeletal muscle, neuronal tissue, and cardiac myocytes. Na/K-ATPase belongs to the 
type-II class of P-type ATPases, and contains four distinct functional domains. The A domain consists 
of the N-terminus and the first cytoplasmic loop connects to transmembrane helices M2 and M3. 
Although there is great sequence variation at the N-terminus between SERCA (sarco/endoplasmic 
reticulum Ca2+-ATPase) and the Na/K-ATPase, both enzymes appear to have the same two α-helix 
motifs. Most importantly, based on the structure of SERCA, the A domain is highly exposed for 
binding of other proteins. The enzyme also has the highly conserved phosphorylation (P) domain 
that is close to the membrane and a relatively isolated nucleotide-binding (N) domain. The structure–
function relationship of Na/K-ATPase was extensively studied in the latter portions of the 20th 
century, and has received new attention due to the recently recognized Na/K-ATPase scaffolding and 
signaling functions. 
Xie Model of Na/K-ATPase Signaling 
The Xie model for the Na/K-ATPase signaling function was derived from difficulties explaining 
signaling with the ionic model, along with experimental observations regarding reactive oxygen 
species (ROS) and tyrosine kinase activities being critical to such signaling. This model proposed that 
the caveolar Na/K-ATPase α1 subunit serves as a negative regulator of Src and that during 
conformational changes in α1 induced by CTS or oxidation, Src is allowed to become active and 
trigger a signal cascade, which involves the generation of ROS. The α1 subunit of the Na/K-ATPase 
binds Src and appears to maintain it in an inactive state. However, binding CTS appears to alter the 
Na/K-ATPase structure allowing Src to become activated, which, in turn, transactivates the EGFR, 
and begins the signal cascade, which causes increases in ROS. 
The Na/K-ATPase-Src complex appears to function similar to a receptor tyrosine kinase. It 
appears that there is a critical binding of the tyrosine kinase domain of Src by a portion of the N 
domain of the α1 subunit. Under basal conditions, this binding inhibits the tyrosine kinase function 
of Src. We speculate that conformational changes induced in Na/K-ATPase by cardiotonic steroids 
and/or the specific oxidation of some amino-acids (vida infra) result in the internalization of this 
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to the membrane and a relatively isolated nucleotide-binding (N) domain. The structure–function
relationship of Na/K-ATPase was extensively studied in the latter portions of the 20th century,
and has received new attention due to the recently recognized Na/K-ATPase scaffolding and
signaling functions.
Xie Model of Na/K-ATPase Signaling
The Xie model for the Na/K-ATPase signaling function was derived from difficulties explaining
signaling with the ionic model, along with experimental observations regarding reactive oxygen
species (ROS) and tyrosine kinase activities being critical to such signaling. This model proposed
that the caveolar Na/K-ATPase α1 subunit serves as a negative regulator of Src and that during
conformational changes in α1 induced by CTS or oxidation, Src is allowed to become active and
trigger a signal cascade, which involves the generation of ROS. The α1 subunit of the Na/K-ATPase
binds Src and appears to maintain it in an inactive state. However, binding CTS appears to alter the
Na/K-ATPase structure allowing Src to become activated, which, in turn, transactivates the EGFR,
and begins the signal cascade, which causes increases in ROS.
The Na/K-ATPase-Src complex appears to function similar to a receptor tyrosine kinase. It appears
that there is a critical binding of the tyrosine kinase domain of Src by a portion of the N domain of
the α1 subunit. Under basal conditions, this binding inhibits the tyrosine kinase function of Src.
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We speculate that conformational changes induced in Na/K-ATPase by cardiotonic steroids and/or the
specific oxidation of some amino-acids (vida infra) result in the internalization of this epitope and the
disinhibition of the tyrosine kinase function of Src with attendant downstream signaling. Downstream
activation of PLC, PI3K and PKC has also been established. This model is shown schematically in
Figure 2, and in our admittedly biased opinion, constitutes an important advance in our understanding
of sodium pump signaling [1].
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Figure 2. Xie Model of Na/K-ATPase Signaling. In this model, cardiotonic steroids (CTS) induce the 
Na/K-ATPase signal cascade, which eventually leads to the development of ROS. We suggest that in 
the microdomain of caveolae, the Na/K-ATPase functions as a scaffolding protein to interact with CTS 
and change conformation to activate Src. Src then transactivates the EGFR, which leads to a signal 
cascade involving FAK, Shc, Grb2 and SOS resulting in the generation of ROS, which in turn activates 
additional Na/K-ATPase molecules, as well as causes downstream activation of ERK and effects 
nuclear transcription. Abbreviations: Epidermal growth factor (EGFR); focal adhesion kinase (FAK); 
Src homology 2 domain protein (Shc); growth factor receptor bound protein 2 Grb2); son of sevenless 
protein (SOS); extracellular-signal-regulated kinase (ERK). 
In recent years, several studies have challenged Xie’s model of direct interaction of c-Src and the 
α1 subunit as this interaction is critical to CTS induced signaling. In Xie’s model, the α1 subunit 
provides the ligand binding site and the associated c-Src functions as the kinase moiety. The 
following evidence supports the notion that Na/K-ATPase directly interacts with Src to form a 
functional receptor complex in live cells [4–8]. Several labs have observed that Na/K-ATPase and Src 
were co-enriched in caveolar fractions in different types of cells. Immunofluorescence has shown co-
localiztion of c-Src and the α1 subunit in the plasma membrane. FRET (fluorescence resonance energy 
transfer) and BRET (bioluminescence resonance energy transfer) analysis indicated that c-Src and the 
α1 were directly interacting in close proximity. Co-immunoprecipitation assays demonstrated direct 
contact of c-Src and the α1 subunit. This subsequently received scrutiny because detergents could 
denature Na/K-ATPase and interactions could be just the interaction of the unfolded Na/K-ATPase 
subunits and Src [9]. However, Tian et al. actually performed the immunoprecipitation assays both 
with and without detergents to control for exactly this [4]. GST pulldown assays demonstrated direct 
interactions between the α1 subunit and Src. They further went on to dissect which domains of Src 
interact with Na/K-ATPase using in vitro binding assays, and found that the Src SH2 domain binds 
to α1 CD2 domain and the Src kinase domain associates with the α1 N domain [10]. 
Figure 2. Xie odel of a/K-ATPase Signaling. In this model, cardiotonic steroids (CTS) induce the
Na/K-ATPase signal cascade, which eventually leads to the development of ROS. We suggest that
in the microdomain of caveolae, the Na/K-ATPase functions as a scaffolding protein to interact with
CTS and change conformation to activate Src. Src then transactivates the EGFR, which leads to a
signal cascade involving FAK, Shc, Grb2 and SOS resulting in the generation of ROS, which in turn
activates additional Na/K-ATPase molecules, as well as causes downstream activation of ERK and
effects nuclear transcription. Abbreviations: Epidermal growth factor (EGFR); focal adhesion kinase
(FAK); Src homology 2 domain protein (Shc); growth factor receptor bound protein 2 Grb2); son of
sevenless protein (SOS); extracellular-signal-regulated kinase (ERK).
In recent years, several studies have challenged Xie’s model of direc interaction of -Src and
the α1 subunit as this interaction is critical to CTS induced signaling. In Xie’s model, the α1 subunit
provi es t ligand binding site and the associated c-Src fun tions as the kinas moiety. The following
evidence supports the notion that Na/K-ATP se directly interacts wi h Src to form a functional receptor
complex in live cells [4–8]. Several lab have observed that Na/K-ATPase and Src were co-enriched
in caveola fractions in diffe en types of c lls. Immunofluorescence has show co-localiztion of
c-Src and the α1 subunit in the plasma membrane. FRET (fluorescence onance energy transfer)
and BRET (bioluminescence reso anc energy transfer) analysis i dicated that c-Src nd the α1 were
directly int racti g in lose proximity. Co-immunoprecipitation assays demonstrated direct contact
f c-Src and the α1 subunit. This subsequently rec ived scrutiny because d tergents could denature
Na/K-ATP se and interactio s could be just the interactio of the unfolded Na/K-ATP se subunits
and Src [9]. However, Tian et al. ac ually performed the immunopreci itation assays both with
and without de ergents to c ntrol f r exactly this [4]. GST pulldo n direct
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interactions between the α1 subunit and Src. They further went on to dissect which domains of Src
interact with Na/K-ATPase using in vitro binding assays, and found that the Src SH2 domain binds to
α1 CD2 domain and the Src kinase domain associates with the α1 N domain [10].
Those who challenged Xie’s model, propose that c-Src activation is primarily due to an
ATP-sparing effect based on cell-free sytem [9,11,12]. Based on Src activity assays performed on
pig kidney cell free mixtures, Gable et al. concluded there that was “no solid evidence for direct
molecular interation of Src with Na/K-ATPase under physiological conditions” [9]. However, similar
to Xie [4], they found that Src-418 phosphorylation was reduced when both Na/K-ATPase and Src were
present in a reaction mixture and that the addition of ouabain partially antagonized the inhibitory effect
of Na/K-ATPase on Src phosphorylation. Unlike Xie, Gable et al. found that vanadate increased Src
phosphorylation (as much as ouabain), indicating that such activation is due to the ATP-sparing effects
of ATPase inhibitors. Yosef et al. performed pulldown assays between recombinant purified human
Src kinase and α1β1FXYD1 and published findings which do not support the direct binding of Src to
Na/K-ATPase in 2016, however they did corroborate a direct caveolin 1 and Na/K-ATPase interaction
in renal membranes [13]. Another study with contradictory results to Xie was by Clifford et al.
who were unable to show a oubain induced interaction between c-Src and α1 by immunoprecipiration
assays in human breast tumor and non-tumorigenic cells [14].
At this time, we are not able to fully explain the dissimilarities in results between all research
groups, but there are noticeable differences in experimental design(different cell lines and animal
models used) at the very least. The Src family consists of at least nine members and many of them
are expressed in a tissue specific manner. The interaction differences we are seeing may constitute
the tissue specific receptor Na/K-ATPase/Src family kinase complex that provides a certain degree
of signaling specificity [15]. Another reason for the discrepancies is that there is still much that is
unknown about the Na/K-ATPase/Src signaling complex, which is why further studies are warranted
to resolve this controversial topic.
3. Oxidative Stress and Regulation of the Na/K-ATPase
Binding of ouabain to Na/K-ATPase activates Src kinase, which in turn transactivates EGFR,
and leads to the activation of the Ras-Raf-MEK-ERK pathway. Ras activation leads to the
activation of MAPK and an increase in [Ca2+], which results in the opening of mitochondrial
ATP-sensitive K+ channels and generation of mitochondrial ROS. Additionally, through the
Na/K-ATPase/c-Src signaling cascade, c-Src activation regulates NOX (NADPH oxidase)-derived
superoxide generation [16]. Conversely, studies have shown that oxidative stress can also activate
Na/K-ATPase signaling in addition to being produced by this pathway.
Increases in ROS can oxidize the Na/K-ATPase α/β subunits and its independent regulator
FXYD proteins. This oxidation inhibits its activity and promotes its susceptibility to degradation by
proteasomal and endosomal/lysosomal proteolytic pathways [17–23]. It appears that the oxidized
modification of Na/K-ATPase is usually a reversible modification [19], however, ROS can accelerate
degradation of the oxidatively damaged Na/K-ATPase [20].
Mechanisms of redox-induced regulation of Na/K-ATPase activity include S-glutathionylation,
S-nitrosylation, carbonylation, phosphorylation, and 4-hydroxynonenal exposure; oxygen-derived free
radicals, H2O2, NO, and oxidized glutathione are the signaling messengers that make Na/K-ATPase
“redox sensitive” in different cell types.
S-glutathionylation of the β1 subunit has been shown to cause a modest, reversible, decrease in
Na/K-ATPase activity in rabbit cardiomyocytes, Xenopus oocytes, and pig kidneys [24,25]. Exposure to
oxidized glutathione results in the presence of S-glutathionylated cysteine residues in the α1 subunit.
This results in a dose and time dependent suppression of Na/K-ATPase function in duck salt glands,
rabbit kidneys, and rat myocardium. [26]. In both α1 and β1 S-glutathionylation, inhibition of
Na/K-ATPase activity occurs via stabilizing the enzyme in the E2 prone conformation or by blocking
the ATP-binding site.
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S-nitrosylation is the modification of the cysteine thiol by incorporation of a NO moiety.
S-nitrosylation of Cys46 in the β-subunit of Na/K-ATPase was reported to cause a 20% decrease
in Na/K-ATPase activity upon exposing cardiomyocytes to hypoxia. Furthermore, S-nitrosylation has
been shown to be necessary as an intermediate step in the induction of regulatory S-glutathionylation
of the β-subunit of Na/K-ATPase [24,25].
Protein carbonylation is another process, which results in the alteration of Na/K-ATPase
function in conditions of oxidative stress [27]. Yan et al. demonstrated that both, CTS and glucose
oxidase-induced H2O2, stimulates direct α1 subunit carbonylation of Pro222 of the actuator(A)
domain and this is involved in a reversible, feed-forward mechanism of regulation of renal proximal
tubule Na/K-ATPase signal transduction [28]. Similarly, in vivo studies have demonstrated that in
obesity models (increased systemic oxidative stress), there is also increased α1 subunit carbonylation
in visceral adipose tissue, which is accompanied by increased Na/K-ATPase pathway signal
transduction-increased phosphorylated c-Src and ERK expression [3].
FXYD proteins associate with the Na/K-ATPase αβ complex, stabilizing it and modulating
the enzyme activity. These modulatory subunits, also known as phospholemman (PLM), may
undergo phosphorylation, however, it is unphosphorylated PLM which has been shown to decrease
Na/K-ATPase function [29]. On the other hand, PKC phosphorylation of Ser36 and Ser68 detaches
PLM inhibition from Na/K-ATPase and increases Na/K-ATPase signaling activity. PLM also contain
cysteine residues that may undergo reversible S-glutathionylation, similar to the α and β subunits.
Thus, interaction between the subunits and the enzyme function is affected by S-glutathionylation of
the PLM [30].
Finally, 4-hydroxynonenal (4-HNE), a lipid peroxidation product, is another oxidative stress
byproduct, which has been shown to inhibit Na/K-ATPase activity, via reacting with sulfhydryl groups
irreversibly [31,32]. Interestingly, Yamaguchi et al. demonstrated decreased α1 protein expression, but
no change with β1 expression, with exposure to 4-HNE in spiral ligament fibrocytes [33]. In summary,
Na/K-ATPase activity and regulation is extremely sensitive to changes in the redox state. Additionally,
while the breadth of literature of how this enzyme is regulated via oxidative mechanisms continues to
grow, it needs to be investigated in greater depth.
4. The Development of pNaKtide
The development of pNaKtide is detailed in our JBC 2009 publication [34]. We identified a portion
of the α1 subunit that could interface with the Na/K-ATPase kinase domain and determined an
effective peptide (NaKtide), which we then merged with a TAT leader sequence to facilitate cellular
permeability. In addition to making the peptide cell permeable, it also appears to localize the peptide
to the membrane component of the cell, restricting its inhibition to the membrane associated portion of
Src. Our data suggest that this results in pNaKtide altering ouabain induced signaling events while
not affecting signal cascades, which are distinct from membrane associated Src. However, this does
not mean that pNaKtide is specific for ouabain or other CTS stimulated pathways, since we have data
suggesting it is effective in disease states where CTS are not implicated (discussed below). pNaKtide,
however, was not the only Src inhibitor. Pyrrolopyrimidines have been reported as potent inhibitors of
c-Src with inhibitory potency at concentrations as low as 10 nM. Other c-Src kinase inhibitors include
quinolinones, which have potencies for in vitro c-Src inhibition at 500 nM, iminochromenes with a
potency of 2 µM, and isothiazolones, which are effective at 4 µM for inhibition of the c-Src family
kinase, p56lck [35]. Herbimycin A and CP-118,556 are also two reagents, which have been shown
to exhibit specificity for inhibition of c-Src. Herbimycin A, a benzoquinone ansamycin antibiotic,
inhibits Src family kinases by disrupting Src interactions with heat shock proteins (especially HSP90).
CP-118,556, a pyrazolopyrimidine, interacts specifically with Src family kinases and is a competitive
inhibitor of ATP, like most other tyrosine kinase inhibitors, which are ATP mimetics [36].
PP2 (4-amino-5-[4-chlorophenyl]-7-[t-butyl] pyrazolo [3,4-d]pyrimidine) is a well-known
generic Src inhibitor, which has been comparatively studied with pNaKtide. Unlike PP2, pNaKtide
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resides in the membranes, and therefore, pNaKtide is effective in disrupting the formation of the
Na/K-ATPase/Src receptor complex in a dose-dependent manner. pNaKtide consequently blocks
ouabain-induced activation of Src, ERK, and hypertrophic growth in cardiac myocytes. Prior studies
by Li et al. have compared pNaKtide and PP2 and while both pNaKtide and PP2 have a similar
IC50 on Src kinase, PP2 produces more inhibition on basal Src activity than that of pNaKtide in both
LLC-PK1 and cardiac myocytes [34]. However, the key difference between PP2 and pNaKtide is that
pNaKtide appears to more specifically target the pool of Na/K-ATPase-interacting Src and has fewer
(off-target) effects than PP2. This was particularly salient to our group since our ultimate goal is
to study the Na/K-ATPase/Src signaling pathway, specifically, as it leads to ROS production and
ultimately oxidative stress related conditions, such as obesity, NASH, atherosclerosis, and diabetes.
Other Src inhibitors do not have the specificity to the Na/K-ATPase complex that pNaKtide does,
therefore they do not afford us the opportunity to study this novel pathway in depth [37].
5. Role of Oxidative Stress and Na/K-ATPase/ROS Signaling in Obesity
Obesity is now a worldwide epidemic, with approximately 400 million considered obese
(BMI ≥ 30) (World Health Organization, Geneva 2006), and poses a major risk for metabolic syndrome
and cardiovascular related mortality [38]. The imbalance of prooxidants and antioxidant defenses
(Figure 3) results in systemic oxidative stress and this is known to play a role in the generation
and maintenance of the obesity phenotype in both isolated adipocytes and intact animals [39–42].
Studies have shown that fat accumulation (obesity) is correlated with systemic oxidative stress in
both humans and mice [43]. Well-known oxidative injury markers, such as MDA (malondialdehyde),
lipid hydroperoxides, conjugated dienes, 4-HNE (4-hydroxynonenal), 8-epi-PGF2α, and TBARS
(thiobarbituric acid reactive substances), have been positively correlated with obesity in human clinical
studies [44,45]. Studies in mouse models of obesity have shown that the production of ROS increases
selectively in white adipose tissue (WAT) of obese mice, suggesting that in obesity, increased oxidative
stress in plasma is due to increased ROS production from accumulated fat [43,46,47]. The WAT, and not
other tissues, of obese mice also has augmented expression of NADPH oxidase (one of the major sources
of ROS in adipocytes) and decreased expression of antioxidant enzymes [43]. In cultured adipocytes,
ROS production is markedly increased during differentiation of 3T3-L1 cells into adipocytes, suggesting
that ROS production increases in parallel with fat accumulation in adipocytes [43,46]. This is supported
by the fact that increasing levels of free fatty acids [48] can induce ROS production through NAPDH
oxidase activation. Further, ROS can upregulate mRNA expression of NADPH oxidase, establishing a
viscous cycle of more ROS production [43].
Adipocyte mitochondrial dysfunction is also proposed as one of the reasons there is increased
ROS production in obesity [38,46]. In mouse models of obesity, the mitochondrial population is
approximately 50% lower in white adipocytes from obese mice, compared to control mice. Furthermore,
about 50% of gene transcripts encoding mitochondrial proteins are decreased with the onset of obesity
in white adipocytes from obese mice compared to control mice [49].
ROS derived from hypertrophied adipocytes may also initiate an inflammatory state in WAT
establishing a feedback loop between inflammation and oxidative stress in obese adipose tissue
furthering WAT dysfunction [46]. Macrophages infiltrate the obese adipose tissues and are an
important source of inflammatory cytokines and possibly augment NADPH oxidase activity and ROS
production. In vitro studies have established that adipocytes exposed to ROS upregulate expression
of proinflammatory cytokines and macrophage chemoattractive molecules, both of which are able to
stimulate more ROS production [50,51], once again highlighting another cycle of ROS production.
There are also several metabolic parameters and complications, which are dysregulated in obesity,
and contribute to and amplify oxidative stress. Hyperglycemia induces oxidative stress through
activation of the polyol and hexosamine pathways, production of advanced glycation end-products
(AGE), and increase of diacylglycerol (DAG) synthesis. Hyperlipidemia induces ROS formation by
increasing lipid oxidation and protein carbonylation. Leptin and angiotensin II, both of which are
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secreted by adipocytes, are inducers of ROS generation. Leptin promotes inflammation and lipid
peroxidation, while angiotensin II stimulates AT1R-NADPH oxidases. Dysregulation of all of these
metabolic parameters with adipose tissue expansion contributes to oxidative stress [45,46].
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Figure 3. Systemic imbalance of prooxidants vs. antioxidants in obesity. Sources of ROS in the
obese state, including the Na/K-ATPase/Src signaling pathway, engage in a positive feedback loop to
produce more ROS, in a setting of limited antioxidant capacity, thereby worsening the existing obesity
and comorbid conditions.
Finally, an obese state is also associated with reduced antioxidant defenses in adipocytes.
For examples, WAT from obese mouse models have decreased expression and activity of antioxidant
enzymes such as SOD, GPX, and catalase [43]. Obese people have low levels of total antioxidants
characterized by lower levels of serum vitamins A, E, C and β-carotene, as well as glutathione [46].
Collectively, the subpar ROS scavenging system might exacerbate the high levels of ROS produced by
hypertrophied adipocytes.
Similarly, our work has focused on targeting a novel oxidative stress signaling pathway which
may balance the prooxidant and antioxidant scales back to equilibrium—the Na/K-ATPase/Src/ROS
amplification loop. Because Na/K-ATPase can amplify oxidant signaling, we speculated that the novel
peptide, pNaKtide, might ameliorate the obesity phenotype. To test this hypothesis, we performed
studies in 3T3-L1 preadipocytes and found that pNaKtide attenuated oxidant stress and lipid
accumulation in a dose-dependent manner. Complementary experiments in C57Bl6 mice fed a high-fat
diet corroborated our in vitro observations. We demonstrated the ability of the Na/K-ATPase signal
cascade to amplify ROS involved in adipogenesis, a process not previously linked to cardiotonic
steroids or the Na/K-ATPase signal cascade. Administration of pNaKtide in these mice reduced body
weight, restored systemic redox and inflammatory milieu, and, crucially, improved insulin sensitivity.
Inhibition of the Na/K-ATPase amplification of oxidative stress may ultimately be a novel way to
combat obesity, insulin resistance, and metabolic syndrome. With this background, we propose that
visceral adipocytes create systemic oxidant stress through the feed-forward oxidant amplification loop
of Na/K-ATPase-Src-EGFR signaling [3].
6. Role of Oxidative Stress and Na/K-ATPase/ROS signaling in Cardiovascular Disease (CVD)
CVDs are a class of pathologies that affect the heart primarily but also include vascular diseases of
the brain, kidney and peripheral arterial system [52]. CVD is the leading cause of mortality in Western
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countries, with approximately 30% of deaths in the United States attributed to it and according to the
World Health Organization; CVD is the principle cause of death globally [48,52,53]. In the vascular
system, under physiological conditions, ROS are produced in low concentrations and act as a signaling
molecule that regulate endothelial function and vascular tone by controlling vascular smooth muscle
cell (VSMC) contraction and relaxation and participate in VSMC growth [54]. Under pathophysiological
conditions, ROS play important roles in various cardiovascular complications including atherosclerosis,
hypertension, congestive heart failure, ischemic heart disease, and ischemia-reperfusion injury.
There are several potential sources of ROS production in CVD including NADPH oxidases (Nox family
of enzymes), xanthine oxidase, mitochondrial dysfunction, and uncoupled nitric oxide synthases [54]
and we suggest, the Na/K-ATPase-Src-EGFR signaling pathway as well.
Oxidative stress plays a central role in the pathogenesis of atherosclerosis, but is also known
to occur in a state of chronic inflammation [55]. Oxidative stress affects transcription factors
(such as NF-xB), which is inactivated by antioxidants and anti-inflammatory agents, suggesting
that atherosclerosis is an inflammatory process, which is strongly affected by oxidative stress [56–58].
ROS produced by endothelial, vascular smooth muscle, and adventitial cells are detrimental to vascular
function by direct injury to cell membranes and nuclei (direct endothelial dysfunction), interacting with
endogenous vasoactive mediators formed in endothelial cells, modulating vasomotion, and via lipid
peroxidation leading to the formation and accumulation of oxidized LDL, one of the key mediators
of atherosclerosis. Our recent in vivo studies have demonstrated that the Na/K-ATPase/Src/ROS
amplification loop is activated by diet-induced oxidative stress, contributing to the development and
progression of dyslipidemia and atherosclerosis. We have shown that the novel pNaKtide has been able
to mitigate both dyslipidemia and atherosclerosis through attenuation of c-Src and ERK1/2 signaling,
which is corroborated with improved plasma ROS and TBARS levels. However, more interestingly,
Na/K-ATPase pathway activation and increased oxidant stress happen despite there being no change
in body weight in an ApoE knockout mouse model of atherosclerosis. This further demonstrates the
importance of the Na/K-ATPase pathway in oxidant stress in CVD and the utility of equilibrating
oxidant stress.
There is both direct and indirect evidence of increased oxidative stress in humans with heart failure.
Patients with heart failure have elevated levels of plasma MDA and pericardial 8-isoprostane. Similar to
obesity, mitochondrial dysfunction, xanthine oxidase, and NAPDH oxidase (Nox4 gene upregulation)
activity is increased, are sources of ROS, and are associated with heart failure [54,59–61]. With regard to
Na/K-ATPase, endomyocardial biopsies have demonstrated that patients with compromised heart
function have total Na/K-ATPase concentrations decreased by 40%, and at the subunit level, the α1-,
α3-, and β1-proteins levels are reduced in human heart failure [62]. Left ventricular hypertrophy (LVH)
and diastolic dysfunction are frequent comorbidities in patients with chronic renal failure. SERCA2a
is a sarcoplasmic reticulum calcium ATPase responsible for the rapid reduction of cytosolic calcium
following systole and is downregulated in experimental chronic renal failure associated LVH [63,64].
Oxidant stress has also been implicated in the pathogenesis of uremic CVD [65]. Our group has
extensive evidence that blockade of Na/K-ATPase signaling results in decreased oxidant stress,
downregulation of SERCA2a and cardiac fibrosis in experimental uremic cardiomyopathy models [66–69].
Almost all experimental models of hypertension display some form of oxidative stress. While,
all vascular cell types produce ROS, NADPH oxidase and mitochondrial enzymes seem to be
particularly important in the development of ROS related to hypertension [70]. Given that
renal function is a key determinant of blood pressure, the ability of oxidative stress to induce
hypertension stems in part from effects on the renal vasculature and nephron [71]. Activation of
the renin-angiotensin system is a major mediator of NADPH oxidase activation and ROS production
in human hypertension [72]. Renal oxidative stress is associated with glomerular damage, proteinuria,
sodium and volume retention, and nephron loss, all of which are important in the development
of hypertension [73,74]. Coordinated regulation of two major ion transporters, the basolateral
Na/K-ATPase and the apical NHE3, has been implicated in high salt intake (volume expansion)
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mediated blood pressure increase. Interestingly, the impairment of the Na/K-ATPase/c-Src signaling
cascade has been shown to contribute to experimental Dahl salt-sensitive hypertension. The effect
and interaction of ROS and Na/K-ATPase on renal proximal tubule sodium reabsorption has been
explored in a limited capacity [71], so, moving forward, it will be key to explore whether ROS signaling
is a link between the Na/K-ATPase/c-Src cascade and NHE3 regulation [16].
7. Conclusions
The Na/K-ATPase/Src signaling pathway highlighted here is a novel mechanism by which
ROS may be produced in pathological conditions related to oxidative stress, such as obesity and
cardiovascular disease. We have much to learn about the mechanisms by which the Na/K-ATPase/Src
signaling pathway contributes to oxidative stress in obesity and CVD, but it is clear, thus far, that ROS
produce, maintain and enhance these diseases states in a positive feedback loop, exacerbating the
redox imbalance. Our novel peptide, pNaKtide, has significant promise in its potential to break the
positive feedback loop of ROS amplification and may have broader applications for other oxidative
stress related pathologies.
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